Form 4 for NRIX Nurix Therapeutics, Inc.
Accepted 2023-12-20 00:00:00 ET · period of report 2023-12-19 · accession 0001549595-23-000064 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-12-20 | 2023-12-19 | NRIX | van Houte Hans | CFO | S - Sale | $10.00 | -10.9K | 75.5K | -13% | -$109.1K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-12-19 | S | D | 10,906 | $10.00 | 75,471 | D | — | — | (F2) Represents the weighted average sale price. The lowest price at which shares were sold was $10.0000 and the highest price at which shares were sold was $10.0200. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein. |